Theratechnologies announces data presentation of SORT1+ technology at AACR

Theratechnologies presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology platform. In a poster session at the 2024 annual meeting of the American Association for Cancer Research AACR in San Diego, Calif., researchers reported that Theratechnologies’ investigational camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer CRC and triple-negative breast cancer TNBC xenograft models. The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads. “The preclinical data presented at AACR add to the sizeable body of evidence supporting the potential utility of the SORT1+ Technology platform as an engine for the development of novel peptide-drug conjugates to treat various types of cancer,” said Christian Marsolais Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. “In addition to our lead peptide-drug conjugate, sudocetaxel zendusortide, these latest data highlight the promising tolerability and anti-tumor effects of our investigational camptothecin-peptide conjugates, further demonstrating the versatility and flexibility of the platform. We welcome discussions with potential partners who are interested in the further development of these innovative therapies.”